XLON
CEL
Market cap11mUSD
Jun 23, Last price
12.00GBP
1D
0.00%
1Q
26.32%
IPO
-90.59%
Name
Celadon Pharmaceuticals PLC
Chart & Performance
P/E
—
P/S
11,015.33
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
75k
+212.50%
Net income
-7m
L-58.99%
CFO
-6m
L-2.10%
Earnings
Sep 29, 2025
Profile
Celadon Pharmaceuticals Plc, a pharmaceutical company, engages in the research, manufacture, and supply of cannabinoids for use in approved medicines. The company focuses on growing indoor hydroponic THC cannabis for use in medicinal products used to treat chronic pain. It also intends to conduct research into cannabinoids for use in chronic pain, as well as other conditions, such as autism and multiple sclerosis. The company was founded in 2018 and is headquartered in London, the United Kingdom.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 75 212.50% | 24 1,100.00% | |||
Cost of revenue | 90 | ||||
Unusual Expense (Income) | |||||
NOPBT | 75 | (66) | |||
NOPBT Margin | 100.00% | ||||
Operating Taxes | (261) | (707) | |||
Tax Rate | |||||
NOPAT | 336 | 641 | |||
Net income | (7,140) -58.99% | (17,411) 264.02% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 2,976 | 7,491 | |||
BB yield | |||||
| Debt | |||||
Debt current | 74 | 66 | |||
Long-term debt | 9,326 | 9,164 | |||
Deferred revenue | |||||
Other long-term liabilities | 405 | 389 | |||
Net debt | 7,923 | 3,951 | |||
| Cash flow | |||||
Cash from operating activities | (5,972) | (6,100) | |||
CAPEX | (341) | (2,086) | |||
Cash from investing activities | (341) | 1,390 | |||
Cash from financing activities | 2,511 | 5,948 | |||
FCF | 189 | 6,599 | |||
| Balance | |||||
Cash | 1,259 | 5,061 | |||
Long term investments | 218 | 218 | |||
Excess cash | 1,473 | 5,278 | |||
Stockholders' equity | (22,323) | (21,398) | |||
Invested Capital | 30,626 | 33,365 | |||
ROIC | 1.05% | 2.67% | |||
ROCE | 0.90% | ||||
| EV | |||||
Common stock shares outstanding | 61,894 | 57,295 | |||
Price | |||||
Market cap | |||||
EV | |||||
EBITDA | 609 | 400 | |||
EV/EBITDA | |||||
Interest | 598 | 4,040 | |||
Interest/NOPBT | 797.33% | ||||